Citations

Clear

35 citation(s) found for "Smits, P".

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Shah, Pankil , Rubinstein, Samuel M. , Joyner, Michael J. , Choueiri, Toni K. , Flora, Daniel , Gulati, Anthony P., Koshkin, Vadim S. , Papadopoulos, Esperanza B. , Robilotti, Elizabeth , Su, Christopher , Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Yu, Peter Paul , Mishra, Sanjay , Senefeld, Jonathon W. , Shah, Dimpy P. , Verma, Amit , Gartrell, Benjamin A. , Ohri, Nitin , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bohachek, Pamela, Mundt, Daniel , Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Revankar, Sanjay G. , Khan, Hina, Prete, Salvatore A. Del , Angevine, Anne H., Bär, Michael , Lo, KM Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Nakayama, John , Gupta, Shilpa , Ahluwalia, Manmeet S. , Dawsey, Scott J. , Nizam, Amanda , Lemmon, Christopher A. , Hoppenot, Claire , Bakouny, Ziad , Bouchard, Gabrielle, Busser, Fiona, Conners, Jean M, Curran, Catherine , Demetri, George D., Kelleher, Kaitlin M. , Shaw, Grace, Nuzzo, Pier Vitale , Zon, Rebecca L. , Zhang, Tian , Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Tachiki, Lisa ML, Vinayak, Shaveta , Wagner, Michael J. , Yeh, Albert C. , Goyal, Sharad , Clément, Jessica , Daher, Ahmad , Dailey, Mark E., Hsu, Emily , Menendez, Alvaro G. , Rathmann, Joerg, Serrano, Oscar K. , Jayaraj, Asha, Accordino, Melissa , Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Shafer, Danielle , Lewis, Mark A. , Rhodes, Terence D., Gill, David , Low, Clarke A., Nagle, Sarah , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Zaren, Howard A. , Smith, Stephanie J., Akhtari, Mojtaba, Lau, Eric , Reeves, Mark E. , Elms, Destry, Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Shah, Surbhi, Rosovsky, Rachel , Reynolds, Kerry L. , Bardia, Aditya , Gainor, Justin F. , Zubiri, Leyre , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Belenkaya, Rimma , Riely, Gregory J. , Faller, Bryan A. , McKay, Rana R. , Ajmera, Archana , Cabal, Angelo , Shaya, Justin , Weissmann, Lisa B., Jani, Chinmay , Chen, James L. , Jhawar, Sachin R, Lustberg, Maryam B. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Karivedu, Vidhya , Addison, Daniel , Menon, Harry, Rovito, Marc A., Elshoury, Amro, Shah, Mansi , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Miller, Chaim , Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Logan, Barbara, Lopes, Gilberto , Russell, Karen , Stith, Brittany, Smits, Melissa, Edwin, Natasha, Chism, David D. , Owenby, Susie, Doroshow, Deborah B. , Galsky, Matthew D. , Zhu, Huili , Fu, Julie , Patel, Kanishka G. , Riess, Jonathan W. , Kwon, Daniel H. , Islam, Jessica Y. , Ahmad, Syed A. , Grover, Punita , Kharofa, Jordan , Marcum, Michelle, Park, Cathleen, Geiger, Christopher L., Bishnoi, Rohit , Feldman, Lawrence , Hoskins, Kent , Gantt, Gerald, Khan, Mahir, Nguyen, Ryan H, Schwartz, Candice, Venepalli, Neeta K. , Kasi, Anup , Fecher, Leslie A. , Mavromatis, Blanche H., Bijjula, Ragneel R., Cheng, Alex , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Reid, Sonya , Slosky, David, Solórzano, Carmen C. , Vega-Luna, Karen, Enriquez, Kyle T. , Sun, Tianyi , Carducci, Theresa M., Puc, Matthew , Loon, Susan Van, Goldsmith, Karen J., Rice, Robert, Cabalona, Wilhelmina D., Pilar, Christine, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Ravindranathan, Deepak , LoRusso, Patricia , Masters, Tyler, Choueiri, Toni K , Bakouny, Ziad , Mishra, Sanjay , Yeh, Albert C , Xie, Zhuoer , Zubiri, Leyre , Su, Christopher , Fiala, Mark A , Joyner, Michael J , Senefeld, Jonathon W , Ahluwalia, Manmeet S , Lustberg, Maryam , Thompson, Michael A. , Henderson, Jeffrey P. , Griffiths, Elizabeth A. , Hwang, Clara , Warner, Jeremy L. , Halmos, Balázs , Goel, Sanjay , Sica, Roberto Alejandro , Thakkar, Astha , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Panagiotou, Orestis A. , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Loaiza‐Bonilla, Arturo , Bar, Michael H, Lo, K. M. Steve, Caimi, Paolo F. , Barnholtz‐Sloan, Jill S. , Pennell, Nathan A , Li, Ang , Giordano, Antonio , Nohria, Anju , Schmidt, Andrew , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Lyman, Gary H , Graber, Jerome J. , Khaki, Ali Raza , Loggers, Elizabeth T , Nakasone, Elizabeth S. , Tachiki, Lisa M, Gatson, Na Tosha , Huynh‐Le, Minh‐Phuong , Rosenstein, Lori J. , Elias, Rawad , Gadgeel, Shirish M. , Hawley, Jessica E. , Hershman, Dawn L. , Bhutani, Divaya , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Nagaraj, Gayathri , Berg, Stephanie , Morgans, Alicia K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Boland, Genevieve M. , Hálfdánarson, Þorvarður R. , Bekaii‐Saab, Tanios , Desai, Aakash , Mesa, Ruben A. , Ramirez, Amelie G , Philip, John , Gatti-Mays, Margaret Elena , Jhawar, Sachin R, Palmer, Joshua D. , Stover, Daniel G. , Joshi, Monika , Jabbour, Salma K , Bashir, Babar , McNair, Christopher M. , Wu, Julie , Kloecker, Goetz Hans , Fazio, Alyson, Kumar, Vaibhav , Wood, William A. , Gulati, Shuchi , Wise-Draper, Trisha Michel , Bowles, Daniel W. , Markham, Merry Jennifer , Shah, Chintan , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H, Pasquinelli, Mary M. , Vikas, Praveen , Friese, Christopher R. , Zaman, Qamar U, Davis, Elizabeth J. , Hausrath, Daniel J. , Hsu, Chih–Yuan , Li, Xuanyi , Rini, Brian I. , Shyr, Yu , Tucker, Matthew D. , Wang, Lucy Lu , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Oncology | August 19, 2021 | Volume: 7 | Issue: 8 | Pages: 1167

10.1001/jamaoncol.2021.1799 | PMID 34137799 Get It

Mucin-derived O -glycans supplemented to diet mitigate diverse microbiota perturbations
Pruss, Kali M. , Marcobal, Ángela, Southwick, Audrey M., Dahan, Dylan , Smits, Sam, Ferreyra, Jessica A., Higginbottom, Steven K. , Sonnenburg, Erica D. , Kashyap, Purna , Choudhury, Biswa, Bode, Lars , Sonnenburg, Justin L. , Sonnenburg, Justin L

Mayo Clinic

The ISME Journal | October 21, 2020 | Volume: 15 | Issue: 2 | Pages: 577-591

10.1038/s41396-020-00798-6 | PMID 33087860 Get It

Abstract Microbiota-accessible carbohydrates (MACs) are powerful modulators of microbiota composition and function. These substrates are often derived from diet, such as complex polysaccharides from plants or human milk oligosaccharides (HMOs) during breastfeeding. Host-derived mucus glycans on gut-secreted mucin proteins serve as a continuous endogenous source of MACs for resident microbes; here we investigate the potential role of purified, orally administered mucus glycans in maintaining a healthy microbial community. In this study, we liberated and purified O-linked glycans from porcine gastric mucin and assessed their efficacy in shaping the recovery of a perturbed microbiota in a mouse model. We found that porcine mucin glycans (PMGs) and HMOs enrich for taxonomically similar resident microbes. We demonstrate that PMGs aid recovery of the microbiota after antibiotic treatment, suppress Clostridium difficile abundance, delay the onset of diet-induced obesity, and increase the relative abundance of resident Akkermansia muciniphila. In silico analysis revealed that genes associated with mucus utilization are abundant and diverse in prevalent gut commensals and rare in enteric pathogens, consistent with these glycan-degrading capabilities being selected for during host development and throughout the evolution of the host–microbe relationship. Importantly, we identify mucus glycans as a novel class of prebiotic compounds that can be used to mitigate perturbations to the microbiota and provide benefits to host physiology.
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas
Boxerman, Jerrold L. , Quarles, C. Chad , Hu, Leland , Gerstner, Elizabeth R. , Smits, Marion , Barboriak, Daniel P. , Huang, Raymond, Wick, Wolfgang , Weller, Michael , Kalpathy–Cramer, Jayashree , Shankar, Lalitha , Jacobs, Paula , Chung, Caroline , Bent, Martin J. van den , Chang, Susan M. , Yung, Wai Kuen, Wen, Patrick Y. , Rosen, Bruce R. , Arons, David F., Kingston, Ann E, Sandak, David, Wallace, M. Z., Musella, Al , Haynes, Chas, Weller, Michael , van den Bent, Martin J , Boxerman, Jerrold L , Wick, Wolfgang , Smits, Marion , Barboriak, Daniel P , Erickson, Bradley J. , Kaufmann, Timothy J. , Galanis, Evanthia , Chang, Susan Marina , Yung, W K Al, Cloughesy, Timothy F. , Wen, Patrick Yung , Gilbert, Mark R. , Ellingson, Benjamin M. , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | June 3, 2020 | Volume: 22 | Issue: 9 | Pages: 1262-1275

10.1093/neuonc/noaa141 | PMID 32516388 Get It

Abstract Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40–50 ms at 1.5 T, 20–35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.
“Real world” use of a highly reliable imaging sign: “T2-FLAIR mismatch” for identification of IDH mutant astrocytomas
Jain, Rajan , Patel, Sohil H. , Smits, Marion , Bent, Martin J. van den , Chi, Andrew S, van den Bent, Martin J , Smits, Marion , Jain, Rajan , Johnson, Derek R. , Castillo, Maurício , Chi, Andrew S, Cahill, Daniel P.

Mayo Clinic

Neuro-Oncology | February 13, 2020 | Volume: 22 | Issue: 7 | Pages: 936-943

10.1093/neuonc/noaa041 | PMID 32064507 Get It

Abstract AbstractThe T2-FLAIR (fluid attenuated inversion recovery) mismatch sign is an easily detectable imaging sign on routine clinical MRI studies that suggests diagnosis of isocitrate dehydrogenase (IDH)–mutant 1p/19q non-codeleted gliomas. Multiple independent studies show that the T2-FLAIR mismatch sign has near-perfect specificity, but low sensitivity for diagnosing IDH-mutant astrocytomas. Thus, the T2-FLAIR mismatch sign represents a non-invasive radiogenomic diagnostic finding with potential clinical impact. Recently, false positive cases have been reported, many related to variable application of the sign’s imaging criteria and differences in image acquisition, as well as to differences in the included patient populations. Here we summarize the imaging criteria for the T2-FLAIR mismatch sign, review similarities and differences between the multiple validation studies, outline strategies to optimize its clinical use, and discuss potential opportunities to refine imaging criteria in order to maximize its impact in glioma diagnostics.
Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases
Smits, Marion , Huang, Raymond Y. , Barboriak, Daniel P. , Weller, Michael , Chung, Caroline , Tsien, Christina , Brown, Paul D. , Shankar, Lalitha , Gerstner, Elizabeth R. , Bent, Martin J. van den , Dunn, Gavin P. , Wen, Patrick Y. , Weller, Michael , van den Bent, Martin J , Smits, Marion , Barboriak, Daniel P , Huang, Raymond , Kaufmann, Timothy J. , Boxerman, Jerrold L. , Galanis, Evanthia , Burns, Terry C. , Parney, Ian F. , Brastianos, Priscilla K. , Lin, Nancy U. , Wen, Patrick Yung , Ellingson, Benjamin M.

Mayo Clinic

Neuro-Oncology | February 7, 2020 | Volume: 22 | Issue: 6 | Pages: 757-772

10.1093/neuonc/noaa030 | PMID 32048719 Get It

AbstractA recent meeting was held on March 22, 2019, among the FDA, clinical scientists, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocacy groups to discuss challenges and potential solutions for increasing development of therapeutics for central nervous system metastases. A key issue identified at this meeting was the need for consistent tumor measurement for reliable tumor response assessment, including the first step of standardized image acquisition with an MRI protocol that could be implemented in multicenter studies aimed at testing new therapeutics. This document builds upon previous consensus recommendations for a standardized brain tumor imaging protocol (BTIP) in high-grade gliomas and defines a protocol for brain metastases (BTIP-BM) that addresses unique challenges associated with assessment of CNS metastases. The “minimum standard” recommended pulse sequences include: (i) parameter matched pre- and post-contrast inversion recovery (IR)–prepared, isotropic 3D T1-weighted gradient echo (IR-GRE); (ii) axial 2D T2-weighted turbo spin echo acquired after injection of gadolinium-based contrast agent and before post-contrast 3D T1-weighted images; (iii) axial 2D or 3D T2-weighted fluid attenuated inversion recovery; (iv) axial 2D, 3-directional diffusion-weighted images; and (v) post-contrast 2D T1-weighted spin echo images for increased lesion conspicuity. Recommended sequence parameters are provided for both 1.5T and 3T MR systems. An “ideal” protocol is also provided, which replaces IR-GRE with 3D TSE T1-weighted imaging pre- and post-gadolinium, and is best performed at 3T, for which dynamic susceptibility contrast perfusion is included. Recommended perfusion parameters are given.
Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea
Battaglioli, Eric , Hale, Vanessa L. , Jeraldo, Patricio , Ruiz-Mojica, Coral, Schmidt, Bradley A., Rekdal, Vayu Maini , Till, Lisa , Huq, Lutfi , Smits, Samuel A. , Moor, William, Jones‐Hall, Yava , Smyrk, Thomas C. , Khanna, Sahil , Pardi, Darrell S. , Grover, Madhusudan , Patel, Robin , Nelson, Heidi D , Sonnenburg, Justin L. , Farrugia, Gianrico , Kashyap, Purna , Battaglioli, Eric J , Jeraldo, Patricio R , Rekdal, Vayu M , Till, Lisa M , Huq, Lutfi , Smits, Samuel A , Moor, William J, Jones-Hall, Yava , Smyrk, Thomas , Grover, Madhusudan , Chia, Nicholas , Sonnenburg, Justin L , Farrugia, Gianrico , Kashyap, Purna C , Patel, Robin , Chen, Jun , Ruiz-Mojica, Coral A. , Chia, Nicholas

Mayo Clinic

Science Translational Medicine | October 24, 2018 | Volume: 10 | Issue: 464 | Pages: No page available

10.1126/scitranslmed.aam7019 | PMID 30355801 Get It

Increased amino acids in the dysbiotic gut influences susceptibility to Clostridioides difficile infection in mice and humans.
HCN1mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond
Marini, Carla , Porro, Alessandro , Rastetter, Agnès, Dalle, Carine, Rivolta, Ilaria , Bauer, Daniel , Oegema, Renske , Nava, Caroline , Parrini, Elena , Mei, Davide , Mercer, Catherine , Dhamija, Radhika , Chambers, Chelsea , Coubes, Christine, Kuentz, Paul , Julia, Sophie , Pasquier, Laurent , Dubourg, Christèle , Carré, Wilfrid , Melani, Federico , Giardino, Maria , Innes, A. Micheil , Alembik, Yves, Scheidecker, Sophie , Figueiroa, Sónia, Garrido, Cristina , Fusco, Carlo , Spagnoli, Carlotta , Binda, Anna , Granata, Tiziana , Ragona, Francesca , Freri, Elena , Franceschetti, Silvana , Canafoglia, Laura , Castellotti, Barbara , Gellera, Cinzia , Milanesi, Raffaella , Mancardi, Maria Margherita , Clark, Damien R, Helbig, Katherine L. , Ichikawa, Shoji , Sadler, Laurie S. , Neupauerová, Jana, Laššuthová, Petra , Štěrbová, Katalin , Laridon, Annick, Brilstra, Eva H. , Koeleman, Bobby P.C. , Striano, Pasquale, Soblet, Julie , Deconinck, Nicolas , Leguern, Éric , Guerrini, Renzo , Santoro, Bina , Hamacher, Kay , Moroni, Anna , DiFrancesco, Jacopo C. , Depienne, Christel , Guerrini, Renzo , Mei, Davide , Pasquier, Laurent , Thévenon, Julien , Rosati, Anna Maria , Pisano, Tiziana , Santos, Manuela M. , Frattini, Daniele , Clark, Damien R., Kok, Fernando , Lemke, Johannes R. , Zara, Federico , Smits, Guillaume , Barbuti, Andrea , DiFrancesco, Dario , Thiel, Gerhard , Depienne, Christel , Dhamija, Radhika

Mayo Clinic

Brain | September 26, 2018 | Volume: 141 | Issue: 11 | Pages: 3160-3178

10.1093/brain/awy263 | PMID 30351409 Get It

Front Cover: Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity (ChemMedChem 18/2018)
Greves, William J., Zwarycz, Angela T. , Smits, Sebastian J. Correa, Troendle, Frederick J., Borosky, Gabriela L. , Chanan‐Khan, Asher , Laali, Kenneth K. , Akhtar, Sharoon , Manna, Alak , Paulus, Aneel , Nukaya, Manabu , Kennedy, Gregory D.

Mayo Clinic

ChemMedChem | September 19, 2018 | Volume: 13 | Issue: 18 | Pages: 1853-1853

10.1002/cmdc.201800584 Get It

Value of MRI in medicine: More than just another test?
Kühl, Christiane , Desmond, Patricia , Gong, Qiyong , Gulani, Vikas , Lim, C. C. Tchoyoson , Pipe, James G. , Smits, Marion , Sodickson, Daniel K. , Tempany, Clare M. , Wang, Meiyun , Smits, Marion , Beek, Edwin J.R. van , Anzai, Yoshimi , Ehman, Richard L. , Gold, Garry Evan , Hall-Craggs, Margaret Anne , Leiner, Tim , Reeder, Scott B. , Reinhold, Caroline , Vargas, Hebert Alberto

Mayo Clinic

Journal of Magnetic Resonance Imaging | August 26, 2018 | Volume: 49 | Issue: 7 | Pages: No page available

10.1002/jmri.26211 | PMID 30145852 Get It

There is increasing scrutiny from healthcare organizations towards the utility and associated costs of imaging. MRI has traditionally been used as a high‐end modality, and although shown extremely important for many types of clinical scenarios, it has been suggested as too expensive by some. This editorial will try and explain how value should be addressed and gives some insights and practical examples of how value of MRI can be increased. It requires a global effort to increase accessibility, value for money, and impact on patient management. We hope this editorial sheds some light and gives some indications of where the field may wish to address some of its research to proactively demonstrate the value of MRI.Level of Evidence: 5Technical Efficacy: Stage 5J. Magn. Reson. Imaging 2019;49:e14–e25.